Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorUniversity of Southern California

About this trial

The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD).

This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison.

Depression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.

Eligibility criteria

Qualifiers

Antidepressant medication treatment is allowed only if the medication dose is stable for 4 weeks prior to the MRI scan.

Psychotherapy interventions is allowed only if they have completed at least 4 weeks of individual or group psychotherapy intervention prior to the MRI scan.

Participants taking cognitive enhancing medications will be able to enter the study.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

120 Participants
are grouped into 1 trial group

Locations

2
University of California, San Francisco94143, San FranciscoCalifornia, United States
University of Pittsburgh15213, PittsburghPennsylvania, United States

Sponsors and collaborators

University of Southern California

Lead sponsor

National Institute of Mental Health (NIMH)

Collaborator

University of California, San Francisco

Collaborator

Alzheimer's Therapeutic Research Institute

Collaborator